The estimated Net Worth of Gerald D. Cagle is at least $658 Thousand dollars as of 8 May 2020. Gerald Cagle owns over 5,000 units of Aerie Pharmaceuticals Inc stock worth over $252,388 and over the last 11 years he sold AERI stock worth over $76,378. In addition, he makes $329,246 as Independent Director at Aerie Pharmaceuticals Inc.
Sign up
Gerald Cagle AERI stock SEC Form 4 insiders trading
Gerald has made over 16 trades of the Aerie Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of AERI stock worth $76,350 on 8 May 2020.
The largest trade he's ever made was exercising 45,454 units of Aerie Pharmaceuticals Inc stock on 11 May 2018 worth over $18,182. On average, Gerald trades about 3,444 units every 70 days since 2014. As of 8 May 2020 he still owns at least 16,550 units of Aerie Pharmaceuticals Inc stock.
You can see the complete history of Gerald Cagle stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gerald Cagle biography
Dr. Gerald D. Cagle Ph.D. serves as Independent Director of the Company. Dr. Cagle was appointed Senior Vice President of Research & Development at Alcon Laboratories Inc. in 1997, a position he held until 2009. From 2009 until his retirement in 2013, Dr. Cagle held the position of Chief Operating Officer at Cognoptix, a company focused on the diagnosis of Alzheimer's disease. Dr. Cagle also serves on the board of directors of GrayBug, Inc., Nacuity, Pharmaceuticals, Inc., and AB2 Bio Ltd. Dr. Cagle received his B.S. from Wayland College, earned both his M.S. and Ph.D. from the University of North Texas and completed the Program for Management Development at Harvard Business School.
What is the salary of Gerald Cagle?
As the Independent Director of Aerie Pharmaceuticals Inc, the total compensation of Gerald Cagle at Aerie Pharmaceuticals Inc is $329,246. There are 11 executives at Aerie Pharmaceuticals Inc getting paid more, with Vicente Anido having the highest compensation of $5,529,670.
How old is Gerald Cagle?
Gerald Cagle is 75, he's been the Independent Director of Aerie Pharmaceuticals Inc since 2013. There are no older and 21 younger executives at Aerie Pharmaceuticals Inc.
What's Gerald Cagle's mailing address?
Gerald's mailing address filed with the SEC is C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM, NC, 27703.
Insiders trading at Aerie Pharmaceuticals Inc
Over the last 11 years, insiders at Aerie Pharmaceuticals Inc have traded over $194,685,628 worth of Aerie Pharmaceuticals Inc stock and bought 2,240,245 units worth $39,233,665 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Anand Mehra, and Capital Management Ii, Llc .... On average, Aerie Pharmaceuticals Inc executives and independent directors trade stock every 45 days with the average trade being worth of $2,718,618. The most recent stock trade was executed by Casey C. Kopczynski on 15 February 2021, trading 60,651 units of AERI stock currently worth $12,130.
What does Aerie Pharmaceuticals Inc do?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
What does Aerie Pharmaceuticals Inc's logo look like?
Complete history of Gerald Cagle stock trades at Aerie Pharmaceuticals Inc, Clearside Biomedical Inc, and Graybug Vision
Aerie Pharmaceuticals Inc executives and stock owners
Aerie Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Vicente Anido,
Chairman of the Board, Chief Executive Officer -
Thomas Mitro,
President, Chief Operating Officer -
John LaRocca,
General Counsel and Assistant Secretary -
Richard Rubino,
Chief Financial Officer, Treasurer, Secretary -
Casey Kopczynski,
Co-Founder, Chief Scientific Officer -
Raj Kannan,
CEO, Principal Financial Officer & Director -
Thomas A. Mitro,
Pres & COO -
Dr. Casey C. Kopczynski,
Co-Founder & Chief Scientific Officer -
John W. LaRocca Esq.,
Gen. Counsel & Sec. -
Dr. David A. Hollander M.B.A., M.D.,
Chief R&D Officer -
Benjamin McGraw,
Lead Independent Director -
Gerald Cagle,
Independent Director -
Julie McHugh,
Independent Director -
David Gryska,
Independent Director -
Mechiel Du Toit,
Independent Director -
Richard Croarkin,
Independent Director -
Dr. Benjamin F. McGraw III, J.D., Pharm.D.,
Exec. Chairman -
Peter McDonnell,
Director -
David Hollander,
Chief Research and Development Officer -
Nina Ohara,
Director of Marketing -
Craig R. Skenes,
Head of Bus. Devel. -
Marvin J. Garrett,
Head of Regulatory Affairs & Quality Assurance -
Wanda Francies,
Head of HR -
Jeffrey M. Calabrese CPA,
VP of Fin. & Principal Accounting Officer -
Dr. Michelle Senchyna Ph.D.,
Head of Clinical Devel. & Operations -
Peter F. Lang,
Chief Financial Officer -
Carolyn McAuliffe,
Sr. Director of Communications -
Evan Hockman,
VP of Sales -
Tad Heitmann,
Head of Communications -
Andrew Allen,
Chief Compliance Officer -
Ami Bavishi,
Director of Investor Relations -
Jeffrey Calabrese,
Director of Accounting -
Toit Michael Du,
Director -
Murray A Goldberg,
Director -
Capital Management Ii, Llc ...,
-
Geoffrey M Duyk,
Director -
Capital Management Ii, Llc ...,
-
Capital Management Ii, Llc ...,
-
James E Deerfield Mgmt L.P....,
-
Anand Healy Jamespowell Mic...,
-
James V Mazzo,
Director -
Group Holdings (Sbs) Adviso...,
-
Brian Levy,
Chief Medical Officer -
Venture Partners Vii L P So...,
-
Iv, L.P.Acmp Iv Llcjanney D...,
-
Lifesciences Ii, L.P.Clarus...,
-
Iv, L.P.Janney Danielnohra ...,
-
Anand Mehra,
Director -
Peter Frederick Lang,
Chief Financial Officer -
Capital Management Iv, Llc ...,
-
Capital Management Ii, Llc ...,
-
Jeffrey Calabrese,
Vice President of Finance -
Christopher Staten,
Interim CFO -
Raj Kannan,
Chief Executive Officer -
Kathleen Mcginley,
CHRO & VP, Corp Services